Principal Investigator: Peter Gottlieb, COMIRB #: 07-1213
The CTLA-4 Ig Research Study is looking for people newly diagnosed with type 1 diabetes.
This research study will use the medication CTLA-4 Ig (Abatacept) to see if we can change the immune system to maintain the body’s ability to produce some insulin.
Why should you consider this study?
- When you are first diagnosed with Type 1 Diabetes you still make some insulin.
- Over time, your body will lose the ability to make this insulin.
- This study will use a medication to try to keep your body making its own insulin.
- While your body continues to make its own insulin, your diabetes will be easier to control.
- Continued production of some insulin can decrease the risk for long term complications of type 1 diabetes.
Who can sign up for this study?
- People recently diagnosed with Type 1 Diabetes within the past 3 months.
- 6 years old - 45 years old.
What will happen in this study?
- You will be assessed for general health and diabetes care.
- If you qualify, you will receive treatment with study medication or fake medication once per month for 2 years.
- You will be monitored for 2 additional years to look at your overall diabetes health.
Who should I call with questions or to schedule an appointment?
Jenna Lungaro: 303.724.6758 or Jenna.Lungaro@ucdenver.edu
Lisa Meyers: 303.724.6893 or Lisa.Meyers@ucdenver.edu
TrialNet website: http://www.diabetestrialnet.org